1 results found.

Recurrent Adult Hodgkin Lymphoma, or Recurrent/Refractory Childho Clinical Trial using brentuximab vedotin; gemcitabine hydrochloride; laboratory biomarker analysis

National Cancer Institute (NCI) - Recruiting 13 Months to 30 years.
- A Phase 1/2 Study of Brentuximab Vedotin (SGN35, IND# 117117) in Combination With Gemcitabine for Pediatric and Young Adult Patients With Relapsed or Refractory Hodgkin Lymphoma.
brentuximab vedotin; gemcitabine hydrochloride; laboratory biomarker analysis